AA
CRNX icon

ALPS Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

ALPS Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.98M Buy
106,409
+21,177
+25% +$787K 0.02% 343
2026
Q1 		$3.1M Buy
85,232
+7,467
+10% +$334K 0.01% 324
2025
Q4 		$3.62M Buy
77,765
+30,350
+64% +$1.35M 0.02% 298
2025
Q3 		$1.97M Sell
47,415
-3,109
-6% -$99.4K 0.01% 382
2025
Q2 		$1.45M Sell
50,524
-16,779
-25% -$518K 0.01% 421
2025
Q1 		$2.26M Sell
67,303
-7,682
-10% -$287K 0.01% 332
2024
Q4 		$3.83M Buy
74,985
+14,242
+23% +$797K 0.02% 264
2024
Q3 		$3.1M Sell
60,743
-782
-1% -$40.3K 0.02% 290
2024
Q2 		$2.76M Buy
61,525
+6,556
+12% +$303K 0.02% 296
2024
Q1 		$2.57M Buy
54,969
+8,944
+19% +$350K 0.02% 312
2023
Q4 		$1.64M Buy
46,025
+5,697
+14% +$175K 0.01% 366
2023
Q3 		$1.2M Buy
40,328
+618
+2% +$12.7K 0.01% 408
2023
Q2 		$716K Buy
39,710
+4,190
+12% +$83.6K 0.01% 552
2023
Q1 		$570K Sell
35,520
-957
-3% -$17.7K 0.01% 569
2022
Q4 		$668K Buy
36,477
+7,151
+24% +$126K 0.01% 539
2022
Q3 		$576K Sell
29,326
-2,414
-8% -$49.2K 0.01% 568
2022
Q2 		$592K Sell
31,740
-17,075
-35% -$341K 0.01% 552
2022
Q1 		$1.07M Sell
48,815
-6,149
-11% -$124K 0.01% 306
2021
Q4 		$1.56M Buy
54,964
+7,528
+16% +$186K 0.02% 316
2021
Q3 		$999K Sell
47,436
-2,080
-4% -$43.5K 0.01% 388
2021
Q2 		$933K Sell
49,516
-10,047
-17% -$177K 0.01% 408
2021
Q1 		$910K Buy
59,563
+126
+0.2% +$1.95K 0.01% 405
2020
Q4 		$839K Buy
59,437
+17,503
+42% +$244K 0.01% 408
2020
Q3 		$657K Sell
41,934
-2,875
-6% -$43.9K 0.01% 396
2020
Q2 		$785K Buy
44,809
+769
+2% +$13.1K 0.01% 369
2020
Q1 		$647K Sell
44,040
-5,132
-10% -$105K 0.01% 393
2019
Q4 		$1.23M Buy
49,172
+955
+2% +$18.2K 0.01% 285
2019
Q3 		$725K Sell
48,217
-2,308
-5% -$44.9K 0.01% 375
2019
Q2 		$1.26M Buy
+50,525
New +$1.25M 0.01% 281

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ALPS Advisors's CRNX Position: Q2 2026 in Review

ALPS Advisors increased its Crinetics Pharmaceuticals (CRNX) stake by 25% in Q2 2026, buying an estimated $787K and bringing the position to 106,409 shares worth $3.98M. The position accounts for 0.02% of the portfolio, ranked #343.

ALPS Advisors first reported a position in CRNX in Q2 2019 and has held it in 29 quarters since. 100 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • ALPS Advisors held 106,409 shares of Crinetics Pharmaceuticals worth $3.98M as of Q2 2026.
  • ALPS Advisors bought 21,177 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $787K.
  • Crinetics Pharmaceuticals made up 0.02% of ALPS Advisors's portfolio in Q2 2026, its #343 holding.
  • ALPS Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • 100 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.